Peripheral T-Cell Lymphoma, Not Otherwise Specified – a case report and short literature review

Rafael Henriques Figueiredo, Beatriz Simao Parreira, Pedro Amoroso Canao, Leila Cardoso, Elsa Fonseca, Jorge Almeida

Abstract


Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common subgroup of peripheral T-cell lymphomas (PTCL), and constitutes a diagnosis of exclusion. At presentation, most patients exhibit B symptoms and generalized lymphadenopathy, with or without concomitant extra-nodal involvement. We present a case of a man admitted to the hospital with B symptoms, generalized lymphadenopathy and a pruritic exanthema. Laboratory workup reveled persistent eosinophilia and malignant hypercalcemia. The excisional lymph node biopsy diagnosed PTCL-NOS, and the skin biopsy demonstrated a lichenoid dermatitis, compatible with the presumptive clinical diagnosis of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. The patient was treated with topical betamethasone with good overall response, and initiated the first cycle of chemotherapy before discharge. This case report describes a PTCL-NOS with a concomitant non-lymphoproliferative disease, the challenging diagnostic workup of the two diseases and reinforces the most important features of the lymphoproliferative neoplasm.

Keywords


Peripheral T-cell lymphoma; PTCL-NOS; lymphadenopathy; DRESS syndrome

Full Text:

PDF

References


Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMID: 35732829; PMCID: PMC9214472, doi: 10.1038/s41375-022-01620-2.

Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019; 134(24):2159-2170. PMID: 31562134; PMCID: PMC6908831, doi: 10.1182/blood.2019000779.

Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017; 129(9):1103-1112. PMID: 28115372, doi: 10.1182/blood-2016-08-692566.

Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008; 49(11):2099-2107. doi: 10.1080/10428190802455867.

Park HS, McIntosh L, Braschi-Amirfarzan M, Shinagare AB, Krajewski KM. T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. Korean J Radiol. 2017; 18(1):71-83. PMID: 28096719; PMCID: PMC5240486, doi: 10.3348/kjr.2017.18.1.71.

Zinzani PL, Broccoli A. T-cell lymphoproliferative disorders. In: Hoffbrand V, Higgs DR, Keeling DM, et al, eds. Postgraduate hematology, 7th ed. Hoboken, NJ: Wiley Blackwell; 2016:524–536.

Choudhary S, McLeod M, Torchia D, Romanelli P. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. J Clin Aesthet Dermatol. 2013; 6(6):31-37. PMID: 23882307; PMCID: PMC3718748.

Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022; 196(3):507-522. PMID: 34811725, doi: 10.1111/bjh.17951.

Gaulard P, de Leval L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin Hematol. 2014; 51(1):5-16. PMID: 24468311, doi: 10.1053/j.seminhematol.2013.11.003.

d’Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v108-115. PMID: 26314772,

doi: 10.1093/annonc/mdv201.

Moon SH, Cho SK, Kim WS, et al. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med. 2013; 54(7):1039-1044. PMID: 23658217, doi: 10.2967/jnumed.112.113399.

Zhang XM, Li YX, Wang WH, et al. Survival advantage with the addition of radiation therapy to chemotherapy in early-stage peripheral T-cell lymphoma, not otherwise specified. Int J Radiat Oncol Biol Phys. 2013; 85(4):1051-1056. PMID: 23021436, doi: 10.1016/j.ijrobp.2012.08.015.

Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992; 117(5):364-370. PMID: 1380221, doi: 10.7326/0003-4819-117-5-364.

Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Erratum in: Lancet. 2019; 393(10168):228. PMID: 30522922; PMCID:

PMC6436818.

Bachy E, Camus V, Thieblemont C, et al. Romidepsin Plus CHOP versus CHOP in patients with previously untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022; 40(3):242-251. PMID: 34843406, doi: 10.1200/JCO.21.01815.

Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011; 22(2):397-404. PMID: 20631009, doi: 10.1093/annonc/mdq359.

Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31(16):1970-1976. PMID: 23610113, doi: 10.1200/JCO.2012.44.7524.




DOI: http://dx.doi.org/10.22551/2022.37.0904.10220

Copyright (c) 2022 Rafael Henriques Figueiredo, Beatriz Simao Parreira, Pedro Amoroso Canao, Leila Cardoso, Elsa Fonseca, Jorge Almeida

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975